Clare Fedele
Affiliations: | 2011-2017 | Peter MacCallum Cancer Centre, Melbourne, Australia |
Google:
"Clare Fedele"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Mark Shackleton | post-doc | 2011-2017 | Peter MacCallum Cancer Centre, Melbourne, Australia |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kuser-Abali G, Zhang Y, Szeto P, et al. (2023) UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma. Oncogene |
| Vergara IA, Mintoff CP, Sandhu S, et al. (2021) Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. Nature Communications. 12: 1434 |
| Noguchi F, Inui S, Fedele C, et al. (2017) Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma. Molecular Cancer Therapeutics. 16: 936-947 |
| Paul PJ, Raghu D, Chan AL, et al. (2016) Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP. Oncogene |
| Alsop K, Thorne H, Sandhu S, et al. (2016) A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology |
| Tan LY, Mintoff C, Johan MZ, et al. (2016) Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget |
| Boyle SE, Fedele CG, Corbin V, et al. (2016) CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. Cancer Research |
| Fedele C, Tothill RW, McArthur GA. (2014) Navigating the challenge of tumor heterogeneity in cancer therapy. Cancer Discovery. 4: 146-8 |
| Gembarska A, Luciani F, Fedele C, et al. (2012) MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine. 18: 1239-47 |